{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T18:23:44Z","timestamp":1766427824568,"version":"3.37.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"BTG International"},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR000064","UL1TR001427"],"award-info":[{"award-number":["UL1 TR000064","UL1TR001427"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40801-024-00435-0","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T18:04:33Z","timestamp":1717610673000},"page":"377-388","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Characterizing Utilization and Outcomes of Digoxin Immune Fab for Digoxin Toxicity"],"prefix":"10.1007","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1939-3126","authenticated-orcid":false,"given":"Sophia","family":"Sheikh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor","family":"Munson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard","family":"Garvan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Layton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawn","family":"Sollee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colleen","family":"Cowdery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexa","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay Schaack","family":"Rothstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgan","family":"Henson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayley","family":"Gartner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Ujhelyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,5]]},"reference":[{"key":"435_CR1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001161","author":"EJ Lavonas","year":"2023","unstructured":"Lavonas EJ, Akpunonu PD, Arens AM, et al. 2023 American Heart Association Focused Update on the Management of Patients With Cardiac Arrest or Life-Threatening Toxicity Due to Poisoning: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2023. https:\/\/doi.org\/10.1161\/CIR.0000000000001161.","journal-title":"Circulation"},{"issue":"7","key":"435_CR2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006035","volume":"6","author":"A Eisen","year":"2017","unstructured":"Eisen A, Ruff CT, Braunwald E, et al. Digoxin use and subsequent clinical outcomes in patients with atrial fibrillation with or without heart failure in the ENGAGE AF-TIMI 48 Trial. J Am Heart Assoc. 2017;6(7): e006035. https:\/\/doi.org\/10.1161\/JAHA.117.006035.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"435_CR3","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/s0735-1097(01)01442-5","volume":"38","author":"MW Rich","year":"2001","unstructured":"Rich MW, McSherry F, Williford WO, Yusuf S, Digitalis Investigation Group. Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. J Am Coll Cardiol. 2001;38(3):806\u201313. https:\/\/doi.org\/10.1016\/s0735-1097(01)01442-5.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"435_CR4","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1161\/CIRCHEARTFAILURE.113.000784","volume":"7","author":"I See","year":"2014","unstructured":"See I, Shehab N, Kegler SR, Laskar SR, Budnitz DS. Emergency department visits and hospitalizations for digoxin toxicity. Circ Heart Fail. 2014;7(1):28\u201334. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.113.000784.","journal-title":"Circ Heart Fail"},{"issue":"1","key":"435_CR5","first-page":"35","volume":"98","author":"R Charfi","year":"2020","unstructured":"Charfi R, Ben Sassi M, Gaies E, Jebabli N, Daghfous R, Trabelsi S. Digoxin therapeutic drug monitoring: age influence and adverse events. Tunis Med. 2020;98(1):35\u201340.","journal-title":"Tunis Med"},{"issue":"2","key":"435_CR6","first-page":"63","volume":"54","author":"M Ujhelyi","year":"1990","unstructured":"Ujhelyi M. Management of digitalis intoxicated patients following the administration of digoxin FAB antibodies (Digibind). Conn Med. 1990;54(2):63\u20134.","journal-title":"Conn Med"},{"issue":"8","key":"435_CR7","doi-asserted-by":"publisher","first-page":"824","DOI":"10.3109\/15563650.2014.943907","volume":"52","author":"BSH Chan","year":"2014","unstructured":"Chan BSH, Buckley NA. Digoxin-specific antibody fragments in the treatment of digoxin toxicity. Clin Toxicol. 2014;52(8):824\u201336. https:\/\/doi.org\/10.3109\/15563650.2014.943907.","journal-title":"Clin Toxicol"},{"issue":"7","key":"435_CR8","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1080\/15563650.2018.1546010","volume":"57","author":"BS Chan","year":"2019","unstructured":"Chan BS, Isbister GK, Page CB, et al. Clinical outcomes from early use of digoxin-specific antibodies versus observation in chronic digoxin poisoning (ATOM-4). Clin Toxicol. 2019;57(7):638\u201343. https:\/\/doi.org\/10.1080\/15563650.2018.1546010.","journal-title":"Clin Toxicol"},{"issue":"5","key":"435_CR9","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jchf.2016.01.011","volume":"4","author":"PJ Hauptman","year":"2016","unstructured":"Hauptman PJ, Blume SW, Lewis EF, Ward S. Digoxin toxicity and use of digoxin immune fab: insights from a National Hospital Database. JACC Heart Fail. 2016;4(5):357\u201364. https:\/\/doi.org\/10.1016\/j.jchf.2016.01.011.","journal-title":"JACC Heart Fail."},{"key":"435_CR10","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.amjcard.2022.08.004","volume":"183","author":"AE Peters","year":"2022","unstructured":"Peters AE, Chiswell K, Hofmann P, Ambrosy A, Fudim M. Characteristics and outcomes of suspected digoxin toxicity and immune fab treatment over the past two decades-2000\u20132020. Am J Cardiol. 2022;183:129\u201336. https:\/\/doi.org\/10.1016\/j.amjcard.2022.08.004.","journal-title":"Am J Cardiol"},{"issue":"2","key":"435_CR11","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/1742-6723.12873","volume":"30","author":"H Arbabian","year":"2018","unstructured":"Arbabian H, Lee HM, Graudins A. Elderly patients with suspected chronic digoxin toxicity: a comparison of clinical characteristics of patients receiving and not receiving digoxin-Fab. Emerg Med Australas EMA. 2018;30(2):242\u20138. https:\/\/doi.org\/10.1111\/1742-6723.12873.","journal-title":"Emerg Med Australas EMA."},{"key":"435_CR12","unstructured":"Champely S. pwr: basic functions for power analysis. 2020."},{"issue":"12","key":"435_CR13","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1513\/AnnalsATS.201506-366BC","volume":"12","author":"HB Gershengorn","year":"2015","unstructured":"Gershengorn HB, Garland A, Gong MN. Patterns of daily costs differ for medical and surgical intensive care unit patients. Ann Am Thorac Soc. 2015;12(12):1831\u20136. https:\/\/doi.org\/10.1513\/AnnalsATS.201506-366BC.","journal-title":"Ann Am Thorac Soc"},{"key":"435_CR14","unstructured":"Ward S. Average wholesale price of DigFab in the US. 2023."},{"issue":"2","key":"435_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1053\/XV.2000.5590","volume":"5","author":"RJ DiDomenico","year":"2000","unstructured":"DiDomenico RJ, Walton SM, Sanoski CA, Bauman JL. Analysis of the use of digoxin immune fab for the treatment of non-life-threatening digoxin toxicity. J Cardiovasc Pharmacol Ther. 2000;5(2):77\u201385. https:\/\/doi.org\/10.1053\/XV.2000.5590.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"4","key":"435_CR16","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1080\/15563650.2021.1968422","volume":"60","author":"BS Chan","year":"2022","unstructured":"Chan BS, Isbister GK, Chiew A, Isoardi K, Buckley NA. Clinical experience with titrating doses of digoxin antibodies in acute digoxin poisoning (ATOM-6). Clin Toxicol. 2022;60(4):433\u20139. https:\/\/doi.org\/10.1080\/15563650.2021.1968422.","journal-title":"Clin Toxicol"},{"key":"435_CR17","unstructured":"BTG International Inc. DIGIFAB DIGOXIN IMMUNE FAB (OVINE). https:\/\/www.fda.gov\/media\/74693\/download. Accessed 4 Dec 2023."}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-024-00435-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-024-00435-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-024-00435-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T03:32:27Z","timestamp":1725161547000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-024-00435-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,5]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["435"],"URL":"https:\/\/doi.org\/10.1007\/s40801-024-00435-0","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"type":"print","value":"2199-1154"},{"type":"electronic","value":"2198-9788"}],"subject":[],"published":{"date-parts":[[2024,6,5]]},"assertion":[{"value":"19 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Funding for this project was provided to the University of Florida by BTG International as a researcher-initiated study. We acknowledge the University of Florida Integrated Data Repository (IDR) and the UF Health Office of the Chief Data Officer for providing the analytic data set for this project. Additionally, the research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under\u202fUniversity of Florida Clinical and Translational Science Awards\u202fUL1 TR000064 and UL1TR001427. The content of this publication, presentation and\/or proposal is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr Sophia Sheikh has no conflicts to report. Ms Munson has no conflicts to report. Mr Garvan has no conflicts to report. Ms Layton has no conflicts to report. Dr Sollee has no conflicts to report. Dr Cowdery has no conflicts to report. Dr Peterson has no conflicts to report. Dr Schaack Rothstein has no conflicts to report. Ms Henson has no conflicts to report. Dr Gartner has no conflicts to report. Dr Michael Ujhelyi is a paid consultant of BTG International.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was approved by the University of Florida\u2019s Institutional Review Board as an exempt study (IRB202201650<b>)<\/b>.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data archiving is not mandated but anonymized data may be available via reasonable request to the corresponding author.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"MU and SS conceived and designed the study and obtained research funding. TM, GG, and CL contributed to the design of the study. SS, TM, and MH supervised the conduct of the trial and data collection. DS, CC, AP, and LSR managed the data, including quality control. GG provided statistical advice on study design and analyzed the data. SS and HG drafted the manuscript, and all authors contributed substantially to its revision. SS takes responsibility for the paper as a whole. All authors read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}